Treatabolome presentations now online

Within the European Solve-RD project, we participate in work to create a “treatabolome” – a database of evidence for treatments for rare disorders linked to the precise genetic defect. Many rare diseases do have treatments available, but frequently there is a substantial delay before patients affected by the disease receive the right treatment. By making this information more readily accessible to clinicians at the time of diagnosis, the treatabolome initiative aims to reduce this treatment delay.

Solve-RD held a treatabolome workshop at ESHG 2020, the aim of which was to show interested clinicians and researchers how to participate in this initiative and create a treatabolome for their own diseases of interest. We are delighted that we are now able to make the presentations available here on the Lochmüller Lab website and we encourage anyone who would like to participate to contact Antonio Atalaia from the Institut de Myologie in Paris, France. Systematic reviews of treatments for neuromuscular diseases may be submitted for a special issue of the Journal of Neuromuscular Diseases, but the concept can be used for any rare disease where treatments are available.

Please view the presentations below and get in touch if you’re interested!

Presentation 1 – Antonio Atalaia – introduction

Presentation 2 – Gisèle Bonne – treatabolome concept

Presentation 3 – Rachel Thompson – systematic reviews

Presentation 4 – Leslie Matalonga – treatabolome database

treatabolome-presentations

Read next...

researcher of the year 2025

Dr. Hanns Lochmüller Awarded “Clinical Researcher of the Year” by University of Ottawa Faculty of Medicine

We are thrilled to announce that Dr. Hanns Lochmüller has been awarded the Clinical Researcher of the Year Award by the University of Ottawa Faculty...
Holland study

New Publication: Galactose treatment rescues neuromuscular junction transmission in glutamine-fructose-6-phosphate transaminase 1 (Gfpt1) deficient mice

Congenital Myasthenic Syndromes (CMS) are a group of rare inherited neuromuscular disorders caused by genetic defects at the neuromuscular junction (NMJ). Patients with CMS experience...
award winners

Celebrating Lab Members’ Recent Research Awards

We are thrilled to celebrate Kelly Ho for receiving first place for her poster presentation at this year’s American Society for Pharmacology and Experimental Therapeutics...
New publication - RTD (2)

Meet The Lochmüller Lab’s Newest Members!

Our research team is growing! We are excited to introduce three new members who have recently joined the Lochmüller lab and several students who will...
McMillan smart study (1)

New Clinical Study Examines Safety and Efficacy of IV Onasemnogene Abeparvovec in Broad SMA Cohort

Pediatric neurologist Dr Hugh McMillan publishes clinical study examining the safety and efficacy of IV onasemnogene abeparvovec in the broadest cohort of SMA patients to...
Text reading: Solve-RD publication: Solve-RD flagship publication: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses. Photos of Dr Kiran Polavarapu, Dr Rachel Thompson, Dr Hanns Lochmüller.

Solve-RD flagship publication in Nature Medicine: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses

Patients and families with rare disorders often remain without a genetic diagnosis despite modern advances in diagnostic testing. Due to the rarity and global distribution...